Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
- Conditions
- Adult Acute Myeloid Leukemia in RemissionExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Adult Burkitt LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Mixed Cell LymphomaNoncontiguous Stage II Adult Immunoblastic Large Cell LymphomaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- Procedure: management of therapy complicationsProcedure: musculoskeletal complications management/prevention
- Registration Number
- NCT01558778
- Lead Sponsor
- Roswell Park Cancer Institute
- Brief Summary
This pilot clinical trial studies mechanical stimulation in preventing bone density loss in patients undergoing donor stem cell transplant. Mechanical stimulation may limit, prevent, or reverse bone loss, increase muscle and cardiac performance, and improve overall health
- Detailed Description
PRIMARY OBJECTIVES:
I. To determine the feasibility of a mechanical stimulation regimen in hematopoietic cell transplant (HCT) patients.
SECONDARY OBJECTIVES:
I. To evaluate the data collection tools to prepare for a larger phase II trial.
OUTLINE:
Patients undergo mechanical stimulation over 20 minutes once daily (QD) beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Meet eligibility criteria for first allogeneic HCT, and are scheduled to undergo allogeneic HCT
- Pre-transplant Karnofsky Performance Status (KPS) >= 70
- Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- Any prior allogeneic HCT
- Pre-transplant weight >= 280 lbs
- Body mass index (BMI) < l8kg/m^2
- Human leukocyte antigen (HLA)-mismatched HCT
- Cord blood transplant
- Osteopenia or osteoporosis (T-score =< -1.0)
- Multiple myeloma diagnosis
- Any prior history of a central nervous system (CNS) hemorrhage
- Currently treated with a therapeutic dose of anti-coagulation for a recent pulmonary embolism or deep vein thrombosis
- Current or previous bisphosphonate use
- Prior history of non-traumatic fracture
- Any screws, pins, rods, or other metal objects in the body
- Total joint replacement
- History of kidney stones or gall stones
- Any artificial limbs
- Pregnant or nursing female patients
- Unwilling or unable to follow protocol requirements
- Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Supportive care (whole body vibration) musculoskeletal complications management/prevention Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant). Supportive care (whole body vibration) management of therapy complications Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
- Primary Outcome Measures
Name Time Method Adherence with treatment From hospital admission to 100 days post-HCT Effective data collection tools and data points From hospital admission to 100 days post-HCT Refinement of mechanical stimulation protocol From hospital admission to 100 days post-HCT Best time of day for treatment, staff involvement, etc.
- Secondary Outcome Measures
Name Time Method